Skip to main content
. 2021 Feb 1;13(3):550. doi: 10.3390/cancers13030550

Figure 1.

Figure 1

Patient flowchart. Patients with ovarian clear cell carcinoma enrolled in the glypican-3 trial were divided into remission and progression groups, and their archival serum samples were used for analysis. GPC3, glypican-3; R, remission; P, progression.